Roles of osteocytes in phosphate metabolism
- PMID: 35909535
- PMCID: PMC9334555
- DOI: 10.3389/fendo.2022.967774
Roles of osteocytes in phosphate metabolism
Abstract
Osteocytes are dendritic cells in the mineralized bone matrix that descend from osteoblasts. They play critical roles in controlling bone mass through the production of sclerostin, an inhibitor of bone formation, and receptor activator of nuclear factor κ B ligand, an inducer of osteoblastic bone resorption. Osteocytes also govern phosphate homeostasis through the production of fibroblast growth factor 23 (FGF23), which lowers serum phosphate levels by increasing renal phosphate excretion and reducing the synthesis of 1,25-dihydroxyvitamin D (1,25(OH)2D), an active metabolite of vitamin D. The production of FGF23 in osteocytes is regulated by various local and systemic factors. Phosphate-regulating gene homologous to endopeptidase on X chromosome (PHEX), dentin matrix protein 1 (DMP1), and family with sequence similarity 20, member C function as local negative regulators of FGF23 production in osteocytes, and their inactivation causes the overproduction of FGF23 and hypophosphatemia. Sclerostin has been suggested to regulate the production of FGF23, which may link the two functions of osteocytes, namely, the control of bone mass and regulation of phosphate homeostasis. Systemic regulators of FGF23 production include 1,25(OH)2D, phosphate, parathyroid hormone, insulin, iron, and inflammation. Therefore, the regulation of FGF23 in osteocytes is complex and multifactorial. Recent mouse studies have suggested that decreases in serum phosphate levels from youth to adulthood are caused by growth-related increases in FGF23 production by osteocytes, which are associated with the down-regulation of Phex and Dmp1.
Keywords: fibroblast growth factor 23; osteoblast; osteocyte; phosphate; regulation.
Copyright © 2022 Michigami.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Osteocytes and the pathogenesis of hypophosphatemic rickets.Front Endocrinol (Lausanne). 2022 Sep 29;13:1005189. doi: 10.3389/fendo.2022.1005189. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36246908 Free PMC article. Review.
-
Osteocyte-specific deletion of Fgfr1 suppresses FGF23.PLoS One. 2014 Aug 4;9(8):e104154. doi: 10.1371/journal.pone.0104154. eCollection 2014. PLoS One. 2014. PMID: 25089825 Free PMC article.
-
Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor 23.Biofactors. 2014 Nov-Dec;40(6):555-68. doi: 10.1002/biof.1186. Epub 2014 Oct 29. Biofactors. 2014. PMID: 25352227 Review.
-
Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1636-44. doi: 10.1152/ajpendo.00396.2007. Epub 2007 Sep 11. Am J Physiol Endocrinol Metab. 2007. PMID: 17848631
-
Growth-related skeletal changes and alterations in phosphate metabolism.Bone. 2022 Aug;161:116430. doi: 10.1016/j.bone.2022.116430. Epub 2022 May 13. Bone. 2022. PMID: 35577326
Cited by
-
Wnt7b overexpression in osteoblasts stimulates bone formation and reduces obesity in mice on a high-fat diet.JBMR Plus. 2024 Sep 23;8(11):ziae122. doi: 10.1093/jbmrpl/ziae122. eCollection 2024 Nov. JBMR Plus. 2024. PMID: 39434845 Free PMC article.
-
X-linked hypophosphatemic rickets: from diagnosis to management.Clin Exp Pediatr. 2024 Jan;67(1):17-25. doi: 10.3345/cep.2022.01459. Epub 2023 Jun 14. Clin Exp Pediatr. 2024. PMID: 37321578 Free PMC article.
-
Mature primary human osteocytes in mini organotypic cultures secrete FGF23 and PTH1-34-regulated sclerostin.Front Endocrinol (Lausanne). 2023 May 8;14:1167734. doi: 10.3389/fendo.2023.1167734. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37223031 Free PMC article.
-
Phosphate in Physiological and Pathological Mineralization: Important yet Often Unheeded.MedComm (2020). 2025 Jul 13;6(7):e70298. doi: 10.1002/mco2.70298. eCollection 2025 Jul. MedComm (2020). 2025. PMID: 40661139 Free PMC article. Review.
-
The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies.Calcif Tissue Int. 2024 Oct;115(4):339-361. doi: 10.1007/s00223-024-01261-w. Epub 2024 Jul 30. Calcif Tissue Int. 2024. PMID: 39078512 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials